Treatment of relapsed or refractory B-cell non-Hodgkin lymphoma with LUCAR-20SP

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical study evaluates the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of LUCAR-20SP, an allogenic CAR-T cell therapy, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Participants will undergo a series of stages including screening, pre-treatment with lymphodepleting chemotherapy, treatment with LUCAR-20SP infusion, and follow-up. The study aims to gather data on the effectiveness of this innovative therapy in managing challenging cases of lymphoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects voluntarily participate in clinical research;
* Age ≥18 years old;
* Eastern Cooperative Oncology Group (ECOG) score 0-1;
* Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, histologically indolent lymphoma to diffuse large B-cell lymphoma; CD20 positive;
* At least one measurable tumor lesion according to the Lugano 2014.
* Expected survival ≥3 months;
* Clinical laboratory values in the screening period meet criteria.
* Effective contraception.

Exclusion Criteria:

* Prior antitumor therapy with insufficient washout period.
* Previous treatment with allogeneic cell and gene therapy (such as CAR-T); Except subjects with evidence that previous allogeneic cell and gene therapy products (such as CAR-positive T cells and CAR transgenes) in the subject have been below the lower limit of detection;
* Previously received allogeneic hematopoietic stem cell transplantation;
* Previously received gene therapy;
* Donor specific antibody (DSA) positive subjects will be excluded;
* Severe underlying diseases;
* Hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C virus ribonucleic acid (HCV RNA) or human immunodeficiency virus antibody (HIV-Ab) positive;
* Presence of other serious pre-existing medical conditions that may limit patient participation in the study. Any condition that, in the investigator's judgment, will make the subject unsuitable for participation in this study.

Where it's running

• Beijing GoBroad Boren Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University Cancer Hospital & Institute
  Beijing, Beijing Municipality, China Recruiting
• Henan Cancer Hospital
  Zhengzhou, China Recruiting

Study contacts

• Study coordinator: Yuqin Song
• Email: songyq22622@163.com
• Phone: 13683398726

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cognitive training to help brain function in people getting CAR-T therapy for relapsed or refractory blood cancers

  A brain-training program given before and after CAR-T therapy is tested to see if it helps cognitive and neurological outcomes for adults with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07609030

• Pomalidomide after CAR T-cell therapy for relapsed or refractory CD19+ B-cell leukemia or lymphoma

  This phase 1 study tests whether pomalidomide, given after CD19 CAR T-cell therapy, is safe and may help people whose CD19+ B-cell leukemia or lymphoma has come back or not responded.

  Recruiting Phase 1 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07532525

• NK cell therapy with epcoritamab and tafasitamab for relapsed or treatment‑resistant B‑cell lymphoma

  This trial will try whether adding donor-derived ONC-PluReceptor NK cells to the antibodies epcoritamab and tafasitamab helps control relapsed or refractory CD19/CD20-positive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283679

• CD19 t-haNK and N-803 plus rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma

  This treatment tests whether giving lab-grown CD19-directed natural killer cells (t-haNK) together with N-803 and rituximab can help adults whose B-cell non-Hodgkin lymphoma has come back or not responded to prior therapy.

  Recruiting at 2 sites Phase 2 ImmunityBio, Inc. · Johannesburg and 1 other locations · NCT07125872

• Epcoritamab and Lenalidomide for Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

  This phase 2 trial checks if the combination of epcoritamab and lenalidomide can help people with immune-related large B-cell lymphoma that hasn’t responded to treatment or has come back.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT06723457

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.